Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System
Kvernland A, Kumar A, Yaghi S, Raz E, Frontera J, Lewis A, Czeisler B, Kahn DE, Zhou T, Ishida K, Torres J, Riina HA, Shapiro M, Nossek E, Nelson PK, Tanweer O, Gordon D, Jain R, Dehkharghani S, Henninger N, de Havenon A, Grory BM, Lord A, Melmed K. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System. Neurocritical Care 2020, 34: 748-759. PMID: 32839867, PMCID: PMC7444897, DOI: 10.1007/s12028-020-01077-0.Peer-Reviewed Original ResearchConceptsHemorrhagic strokeTherapeutic anticoagulationClinical characteristicsThrombotic complicationsHistorical controlsCOVID-19Exact testHigher initial NIHSS scoreSARS-CoV-2 patientsInitial NIHSS scoreRetrospective cohort studyHealthcare systemFischer's exact testCOVID-19 infectionNon-aneurysmal SAHMajor healthcare systemOverall low rateAnticoagulation useEmpiric anticoagulationHospital mortalityNIHSS scoreCohort studyCommon etiologyIntraparenchymal hemorrhageMost hemorrhages